Kelly Nelle

Paralegal Specialist
Full contact info

Experience

RayzeBio Announces Upsized $357.6 Million IPO

September 19, 2023

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.

Read more

Related contacts

Carlos Ramirez
Partner, San Diego
Charlie Kim
Partner, San Diego
Marya Postner
Partner, Palo Alto
Terren O'Connor
Associate, San Diego
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Jayden Martinez
Associate, Colorado
Michelle Hunt
Associate
Todd Gluth
Partner, San Diego
Tony P. Guan
Associate, Los Angeles Santa Monica
Nathaniel Hearn Jr.
Associate, New York
Daniel Lac
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
Kelly Nelle
Paralegal Specialist, San Diego
Rebecca Ross
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Jeffrey J. Tolin
Partner, New York
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Poseida Therapeutics – $80.5 Million Follow-on Offering

September 7, 2022

Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.

Related contacts

Tom Coll
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Special Counsel, San Diego
Edmond Lay
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

The Underwriters On Guardant Health's $1.1 Billion Follow-On Offering

June 8, 2020

Advised underwriters on Guardant Health's $1.1 billion follow-on offering. Guardant Health, whose securities trade on the Nasdaq Global Select Market under the symbol “GH”, is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics

Related contacts

David Peinsipp
Partner, San Francisco
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Kelly Nelle
Paralegal Specialist, San Diego